{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:37:58Z","timestamp":1764322678231,"version":"3.46.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.hpb.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:56:01Z","timestamp":1758592561000},"page":"1563-1574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring adjuvant chemotherapy for gallbladder cancer: moving beyond one-size-fits-all strategy"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2456-5413","authenticated-orcid":false,"given":"Yuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2025.09.006_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hpb.2025.09.006_bib2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2018.11815","article-title":"Gallbladder cancer","volume":"320","author":"Baiu","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.hpb.2025.09.006_bib3","doi-asserted-by":"crossref","first-page":"18861","DOI":"10.1002\/cam4.6513","article-title":"Improved long-term outcomes after innovative preoperative evaluation and conception of precise surgery for gallbladder cancer","volume":"12","author":"Jia","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.hpb.2025.09.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.09.006_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/s12885-015-1617-y","article-title":"Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis","volume":"15","author":"Ma","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hpb.2025.09.006_bib6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib7","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1245\/s10434-023-13567-4","article-title":"Trends in receipt of adjuvant chemotherapy and its impact on survival in resected biliary tract cancers","volume":"30","author":"Rhodin","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib8","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1097\/JS9.0000000000001403","article-title":"Prognostic factors for resected cases with gallbladder carcinoma: a systematic review and meta-analysis","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.hpb.2025.09.006_bib9","first-page":"109","article-title":"Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival","author":"Mitin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hpb.2025.09.006_bib10","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102975","article-title":"Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials","volume":"151","author":"Belkouz","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.hpb.2025.09.006_bib12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.hpb.2020.02.001","article-title":"Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers","volume":"22","author":"Ma","year":"2020","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2025.09.006_bib13","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","article-title":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","volume":"29","author":"Wang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib14","article-title":"Neoadjuvant and adjuvant therapy for biliary tract cancer: advances and limitations","author":"Wilbur","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2025.09.006_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51502","article-title":"Adjuvant chemotherapy and outcomes in older adult patients with biliary tract cancer","volume":"7","author":"Gbolahan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpb.2025.09.006_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.hpb.2025.09.006_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00423-023-03119-5","article-title":"Metastatic lymph node ratio as an important prognostic factor in advanced gallbladder carcinoma with at least 6 lymph nodes retrieved","volume":"408","author":"Wang","year":"2023","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.hpb.2025.09.006_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13144201","article-title":"Risk factors and prognostic factors in GBC","volume":"13","author":"Tirca","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.hpb.2025.09.006_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11605-009-1140-z","article-title":"Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma","volume":"14","author":"Kim","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.hpb.2025.09.006_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030547","article-title":"Validation of the 8th edition American joint commission on cancer (AJCC) gallbladder cancer staging system: prognostic discrimination and identification of key predictive factors","volume":"13","author":"Giannis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hpb.2025.09.006_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3389\/fonc.2019.01329","article-title":"Prognostic model to predict cancer-specific survival for patients with gallbladder carcinoma after surgery: a population-based analysis","volume":"9","author":"He","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib22","doi-asserted-by":"crossref","first-page":"16466","DOI":"10.1038\/s41598-022-20933-x","article-title":"A novel nomogram based on log odds of positive lymph nodes to predict survival for non-metastatic gallbladder adenocarcinoma after surgery","volume":"12","author":"Jiang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.hpb.2025.09.006_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225580","article-title":"Gallbladder cancer: current multimodality treatment concepts and future directions","volume":"14","author":"Sturm","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hpb.2025.09.006_bib24","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.clinre.2021.101788","article-title":"The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: a systematic review and meta-analysis","volume":"46","author":"Song","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.hpb.2025.09.006_bib25","article-title":"Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.hpb.2025.09.006_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-2438","article-title":"Facts and hopes in the systemic therapy of biliary tract carcinomas","author":"Lamarca","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hpb.2025.09.006_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijsu.2018.02.052","article-title":"Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial? (Results of a US-national retrospective cohort study)","volume":"52","author":"Bergquist","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.hpb.2025.09.006_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108047","article-title":"Survival benefit of adjuvant chemotherapy in patients with resected gallbladder adenocarcinoma: an updated retrospective cohort analysis","volume":"50","author":"Wang","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1245\/s10434-020-08973-x","article-title":"Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients","volume":"28","author":"Kemp Bohan","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.09.006_bib30","first-page":"931","article-title":"Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)","volume":"19","author":"Lee","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.hpb.2025.09.006_bib31","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"Swog S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25016223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25016223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:34:03Z","timestamp":1764322443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X25016223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1365182X25016223"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2025.09.006","relation":{},"ISSN":["1365-182X"],"issn-type":[{"type":"print","value":"1365-182X"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring adjuvant chemotherapy for gallbladder cancer: moving beyond one-size-fits-all strategy","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}